We are live on ! Find out more
KNTE

Kinnate Biopharma Inc. Common Stock
KNTE

Delisted

KNTE was delisted on the 2nd of April, 2024.

Back to rankings

71 hedge funds and large institutions have $750M invested in Kinnate Biopharma Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 14 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

79% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 14

67% more funds holding in top 10

Funds holding in top 10: 3 → 5 (+2)

3% less funds holding

Funds holding: 73 → 71 (-2)

17% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 12

17% less capital invested

Capital invested by funds: $905M → $750M (-$155M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $23K

Holders
71
Holders Change
-2
Holders Change %
-2.74%
% of All Funds
1.09%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.08%
New
10
Increased
25
Reduced
14
Closed
12
Calls
–
Puts
$23K
Net Calls
-$23K
Net Calls Change
-$23K

Top Buyers

Rank Fund Capital Flow
1
N
Natixis
France
+$14.2M
2
BlackRock
BlackRock
New York
+$3.64M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.28M
4
State Street
State Street
Massachusetts
+$1.19M
5
NHAS
Novo Holdings A/S
Denmark
+$1.15M

Top Sellers

Rank Fund Capital Flow
1
VA
VR Adviser
New York
-$14.8M
2
Morgan Stanley
Morgan Stanley
New York
-$7.75M
3
Millennium Management
Millennium Management
New York
-$2.73M
4
LGM
Logos Global Management
California
-$2.17M
5
DM
Deerfield Management
New York
-$906K
Name Holding Trade Value Shares
Change 		Change in
Stake
FCMI
1
Foresite Capital Management IV
California
$171M – – –
O
2
OrbiMed
New York
$68.2M – – –
RCM
3
RA Capital Management
Massachusetts
$63.7M – – –
NI
4
Nextech Invest
Switzerland
$53.3M +$63.4M +3,008,243 New
VVA
5
Vida Ventures Advisors
Massachusetts
$48.7M – – –
Fidelity Investments
6
Fidelity Investments
Massachusetts
$37.1M -$102K -4,823 -0.2%
BlackRock
7
BlackRock
New York
$36.3M +$3.64M +172,674 +9%
Vanguard Group
8
Vanguard Group
Pennsylvania
$34.1M +$1.28M +60,815 +3%
BC
9
Boxer Capital
California
$32.7M – – –
Viking Global Investors
10
Viking Global Investors
Connecticut
$32.3M – – –
Citadel Advisors
11
Citadel Advisors
Florida
$19.9M -$687K -32,569 -3%
DM
12
Deerfield Management
New York
$17.5M -$906K -42,940 -4%
FCMV
13
Foresite Capital Management V
California
$15.5M – – –
VA
14
VR Adviser
New York
$13.7M -$14.8M -700,000 -48%
N
15
Natixis
France
$11.9M +$14.2M +672,500 New
NHAS
16
Novo Holdings A/S
Denmark
$9.8M +$1.15M +54,600 +11%
HMC
17
Harvard Management Company
Massachusetts
$8.82M – – –
State Street
18
State Street
Massachusetts
$6.89M +$1.19M +56,355 +17%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$6.44M +$557K +26,410 +8%
RSCM
20
Rock Springs Capital Management
Maryland
$6.02M +$145K +6,860 +2%
Federated Hermes
21
Federated Hermes
Pennsylvania
$5.45M – – –
FCOMV
22
Foresite Capital Opportunity Management V
California
$5.17M +$6.15M +291,667 New
PHS
23
PFM Health Sciences
California
$4.68M – – –
WP
24
Woodline Partners
California
$4.61M – – –
American Century Companies
25
American Century Companies
Missouri
$3.79M +$840K +39,855 +23%
1
2 3 4

KNTE Hedge Fund Activity: Q4 2021 in Review

71 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q4 2021, worth a combined $750M — down 17% from $905M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of KNTE and 10 opened new positions — a net loss of 2 holders — while 14 trimmed existing stakes and 25 added.

The largest buyer was Natixis, opening a new position worth an estimated $14.2M. The largest seller was VR Adviser, cutting an estimated $14.8M.

  • 71 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q4 2021, down from 73 in Q3 2021.
  • Funds reported $750M of Kinnate Biopharma Inc. Common Stock stock for Q4 2021, down 17% quarter-over-quarter.
  • 10 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q4 2021 and 12 closed out, a net change of -2 holders.
  • The largest Kinnate Biopharma Inc. Common Stock buyer in Q4 2021 was Natixis, an estimated $14.2M added.
  • The largest Kinnate Biopharma Inc. Common Stock seller in Q4 2021 was VR Adviser, an estimated $14.8M sold.

Based on aggregated 13F filings for Q4 2021.